Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TGTX | TG THERAPEUTICS INC | $5.82B | $36.71 | $55.00 | 49.84% | Strong Buy | 1 | 28.60% | 77.54% | 189.41% | 74.52% | |||
| CORT | CORCEPT THERAPEUTICS INC | $9.29B | $88.15 | $135.33 | 53.53% | Strong Buy | 3 | 28.79% | 49.01% | 128.03% | 101.53% | |||
| CRMD | CORMEDIX INC | $769.13M | $11.34 | $18.20 | 60.49% | Buy | 5 | 77.60% | 119.06% | 167.96% | 129.00% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.85B | $38.49 | $48.25 | 25.36% | Strong Buy | 4 | 21.07% | 228.28% | 42.44% | 31.78% | |||
| HALO | HALOZYME THERAPEUTICS INC | $8.07B | $68.98 | $77.17 | 11.87% | Buy | 6 | 16.15% | 24.64% | 308.98% | 50.06% | |||
| KRYS | KRYSTAL BIOTECH INC | $5.31B | $183.36 | $195.57 | 6.66% | Strong Buy | 7 | 33.35% | 32.64% | 36.39% | 33.27% | |||
| ARGX | ARGENX SE | $48.83B | $800.00 | $834.69 | 4.34% | Strong Buy | 13 | 1,386.97% | 7.46% | 35.27% | 29.96% | |||
| INVA | INNOVIVA INC | $1.10B | $17.48 | $30.75 | 75.92% | Buy | 4 | 12.10% | 60.24% | 26.89% | 14.41% | |||
| VCEL | VERICEL CORP | $1.64B | $32.44 | $58.67 | 80.85% | Strong Buy | 3 | 19.25% | 84.91% | 24.83% | 17.49% | |||
| RPRX | ROYALTY PHARMA PLC | $21.04B | $36.07 | $46.00 | 27.53% | Strong Buy | 3 | 19.41% | 47.53% | 33.17% | 17.20% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.49B | $11.35 | $13.00 | 14.54% | Buy | 2 | 13.23% | 17.95% | 20.02% | 13.36% | |||
| INCY | INCYTE CORP | $16.96B | $86.85 | $83.91 | -3.39% | Buy | 11 | 8.57% | 22.63% | 42.98% | 30.79% | |||
| EXEL | EXELIXIS INC | $10.79B | $40.09 | $46.31 | 15.52% | Buy | 16 | 10.26% | 17.91% | 69.43% | 52.72% | |||
| GYRE | GYRE THERAPEUTICS INC | $713.68M | $7.41 | $18.00 | 142.91% | Buy | 1 | 16.64% | 11.68% | 303.51% | 182.98% | |||
| ADMA | ADMA BIOLOGICS INC | $3.50B | $14.66 | $32.00 | 118.28% | Strong Buy | 1 | 18.62% | 13.60% | 100.65% | 71.80% | |||
| MDXG | MIMEDX GROUP INC | $1.07B | $7.21 | $12.00 | 66.44% | Strong Buy | 1 | 10.22% | 42.65% | N/A | N/A | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.57B | $27.28 | $49.25 | 80.54% | Strong Buy | 8 | 13.33% | 15.81% | 44.83% | 31.28% | |||
| ATRA | ATARA BIOTHERAPEUTICS INC | $101.20M | $14.41 | N/A | N/A | N/A | N/A | N/A | 24.54% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $9.79B | $62.95 | $68.38 | 8.62% | Strong Buy | 8 | 4.69% | 106.41% | 16.23% | 12.18% | |||
| VCYT | VERACYTE INC | $2.82B | $36.00 | $40.00 | 11.11% | Strong Buy | 3 | 8.74% | 49.47% | 7.44% | 6.76% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.64B | $55.43 | $95.86 | 72.93% | Strong Buy | 7 | 7.44% | 18.16% | 21.19% | 17.12% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $103.40B | $403.30 | $486.06 | 20.52% | Buy | 17 | 7.31% | 10.69% | 33.80% | 24.15% | |||
| GMAB | GENMAB A | $21.53B | $33.56 | $43.00 | 28.13% | Strong Buy | 4 | 16.17% | 7.73% | 4.85% | 3.98% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.55B | $20.84 | N/A | N/A | N/A | N/A | 7.50% | 13.43% | 38.03% | 33.50% | |||
| NVO | NOVO NORDISK A S | $266.25B | $59.63 | $62.75 | 5.23% | Buy | 4 | 3.65% | 5.11% | 97.75% | 34.07% | |||
| MNKD | MANNKIND CORP | $1.77B | $5.76 | $11.00 | 90.97% | Strong Buy | 4 | 10.83% | 8.37% | -211.83% | 28.32% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.